DDInter1388 DDInter119
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Pantoprazole {u} (Compound) binds {v} (Gene) ATP4B
Pantoprazole {u} (Compound) upregulates {v} (Gene) TCTN1
Pantoprazole {u} (Compound) downregulates {v} (Gene) ACAT2
Pantoprazole {u} (Compound) causes {v} (Side Effect) Jaundice cholestatic
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cefditoren
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Pantoprazole (Compound) resembles Omeprazole (Compound)
Pantoprazole (Compound) binds ATP4B (Gene)
Pantoprazole (Compound) upregulates TCTN1 (Gene)
Pantoprazole (Compound) downregulates ACAT2 (Gene)
Pantoprazole (Compound) causes Jaundice cholestatic (Side Effect)
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Pantoprazole may lead to a major life threatening interaction when taken with Atazanavir